Edwards Lifesciences recommended on weakness at Canaccord Canaccord recommends accumulating Edwards Lifesciences on weakness and views 2014 guidance as a worse case scenario. The firm recommends looking past 2014 competitive pressures into 2015/16 when comps are easier and business prospects are better. Shares are Buy rated with a $74 price target, down from $76.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
Edwards Lifesciences upgraded to Outperform from Market Perform at Wells Fargo Wells Fargo upgraded Edwards Lifesciences citing a number of positive developments since it downgraded the stock in December 2013, including strong Q4 Sapien results outside the U.S. and the company's successful first-inman transcatheter mitral valve implants. Wells raised its price target range for shares to $82-$83 from $67-$69.